Trial Profile
Retrospective Medical Chart Review Study for Atrial Fibrillation Patents Treated With Oral Anticoagulant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Warfarin (Primary)
- Indications Stroke; Thrombosis
- Focus Adverse reactions
- Acronyms RCR-OAC
- Sponsors Bristol-Myers Squibb
- 12 May 2022 Status changed from active, no longer recruiting to completed.
- 10 Dec 2021 Results published in the Circulation Journal
- 12 Dec 2018 New trial record